COVID-19 and Ebola: Rethinking Pandemic Preparedness After the World's Largest Pandemic

Introducing Sequential Pathogen Burden™: A Framework for Viral Persistence, Immune Fragility, and Future Outbreak Risk

By: Cynthia Adinig

Executive Summary

Modern infectious disease preparedness has been built around the acute phase of illness. Surveillance systems quantify infections, hospitalizations, and deaths, while public health interventions focus on interrupting transmission, reducing mortality, and restoring population health. This framework transformed outbreak response over the past century and remains indispensable. Increasing evidence from SARS-CoV-2, Ebola virus, Epstein-Barr virus, cytomegalovirus, herpesviruses, and other persistent pathogens, however, demonstrates that biological recovery does not always coincide with clinical recovery. Viral persistence, latent pathogen reactivation, immune remodeling, chronic inflammation, tissue-specific reservoirs, and infection-associated chronic conditions may continue months or years after apparent resolution of acute disease (Peluso et al., 2024; Proal and VanElzakker, 2021; Davis et al., 2023; Naderi et al., 2025; Stein et al., 2022; Liu et al., 2022; Keita et al., 2021).

COVID-19 fundamentally changed the scale at which these biological processes can be observed. Rather than occurring within isolated patient populations or individual disease specialties, post-acute infectious sequelae emerged simultaneously across billions of people. Future outbreaks therefore will not encounter the same host population that existed before 2020. They will spread through populations shaped by repeated SARS-CoV-2 infections, evolving immune histories, infection-associated chronic conditions, and cumulative pathogen exposure (Altmann et al., 2023; Brodin and Casari, 2023; Zhang et al., 2026; Maier et al., 2025).

The central premise of this paper is that preparedness has spent the past century measuring pathogens. The next century may require measuring the populations those pathogens encounter.

To address this shift, this paper introduces Sequential Pathogen Burden (SPB), a preparedness framework describing how successive infections, latent pathogen reactivation, microbial interactions, cumulative immune remodeling, and incomplete biological recovery shape long-term host resilience following major infectious events. Rather than replacing traditional outbreak models, SPB extends preparedness beyond acute infection by recognizing that pathogens interact with an evolving biological landscape rather than a biologically static population (Virgin, Wherry and Ahmed, 2009; Narasaraju, Chow and Pandareesh, 2024; Naderi et al., 2025).

Building upon this parent framework, the paper introduces three operational preparedness constructs. The Immune Fragility Population (IFP-US) estimates hidden population vulnerability beyond recognized infection-associated chronic conditions. The Ebola Host Susceptibility Mortality Shift (EHS-MS) models how changes in host resilience may amplify mortality during future outbreaks without requiring changes in pathogen virulence. The Immune Fragility Economic Burden (IFEB) estimates the long-term healthcare, workforce, and societal costs associated with a biologically less resilient population (Adinig, US-CCUC, 2026; Adinig, PCT, 2026).

Using CYNAERA’s US-CCUC baseline, the framework estimates that approximately 75 to 90 million Americans are currently living with at least one infection-associated chronic condition, including 25 to 35 million with multiple overlapping IACCs. SPB further estimates that an additional 40 to 100 million Americans may belong to the proposed Immune Fragility Population, producing a combined higher-risk preparedness population of approximately 115 to 190 million Americans, or 34% to 56% of the U.S. population.

Applying these preparedness scenarios globally suggests that approximately 2.8 to 4.6 billion people could fall within a higher-risk immune fragility population, although country-specific estimates would vary substantially by demographics, infectious disease burden, healthcare ac cess, baseline chronic illness prevalence, and prior SARS-CoV-2 exposure. These estimates are presented as preparedness scenarios rather than disease-prevalence claims and are intended to support planning under uncertainty, not to establish diagnostic categories.

Taken together, these findings suggest that post-pandemic changes in host resilience may represent one of the largest hidden public health burdens ever modeled (Adinig, US-CCUC, 2026).

Applying the framework to the ongoing Bundibugyo virus Ebola outbreak illustrates the potential impact of changes in host resilience. Under standardized preparedness scenarios, relatively modest host susceptibility shifts increase projected mortality despite no change in viral genetics or baseline virulence. At the current outbreak size, modeled excess mortality ranges from approximately 23 to 136 additional deaths, while a standardized 10,000-case outbreak produces approximately 309 to 927 excess deaths under moderate to severe host susceptibility scenarios. Over a ten-year planning horizon, the framework estimates a potential U.S. economic burden of $900 billion to $3.4 trillion, with corresponding global preparedness scenarios ranging from $5 trillion to $20 trillion (WHO, 2026; ECDC, 2026; Cutler, 2022; Al-Aly et al., 2024; Adinig, US-CCUC, 2026).

Collectively, these frameworks propose a shift from pathogen-centered preparedness toward host-pathogen preparedness. The question is no longer solely how pathogens evolve, but whether the biological characteristics of the populations they infect have fundamentally changed. If so, preparedness models built upon pre-pandemic assumptions may systematically underestimate future healthcare demand, outbreak severity, and long-term societal burden.

1. Recovery Is Not Always Resolution

The 2026 outbreak of Ebola disease in the Democratic Republic of the Congo, caused by Bundibugyo virus, has renewed global attention to one of the most lethal groups of pathogens known. Public health agencies have emphasized surveillance, contact tracing, vaccine research, infection control, and clinical management. The outbreak also highlights a less discussed aspect of filovirus biology: recovery from acute infection does not always represent the end of biological risk. Studies of Ebola survivors, predominantly involving Zaire ebolavirus, have demonstrated persistent viral reservoirs within immune-privileged tissues including the brain, eye, and testes, with documented recrudescence months or years after apparent recovery, and in rare instances new chains of human transmission (Liu et al., 2022; Vetter et al., 2016; Meek et al., 2025; Keita et al., 2021).

Ebola provides a dramatic example, but it is not unique. Persistent infection, latent viral reactivation, immune remodeling, and prolonged host-pathogen interaction are recognized across multiple viral families, including Epstein-Barr virus, cytomegalovirus, herpes simplex virus, varicella-zoster virus, hepatitis B virus, and human immunodeficiency virus (Virgin et al., 2009; Naderi et al., 2025; Proal and VanElzakker, 2021; Iwasaki and Putrino, 2023). These phenomena have historically been studied within disease-specific silos: virologists study latency, immunologists study host response, infectious disease specialists manage acute illness, and chronic disease researchers examine sequelae. COVID-19 blurred those boundaries by generating unprecedented interest in persistence, reservoirs, immune dysregulation, and infection-associated chronic illness.

Preparedness science has traditionally focused on the pathogen. Models estimate transmission, agencies monitor case counts, laboratories characterize viral evolution, and health systems prepare for projected demand. Comparatively little attention has been directed toward whether the host population itself has changed following the largest pandemic in modern history. Outbreak severity reflects not only pathogen characteristics but also host susceptibility, immune resilience, prior infection history, and healthcare capacity. If those host characteristics have shifted at population scale, models built on pre-pandemic assumptions may underestimate future burden (Altmann et al., 2023; Brodin and Casari, 2023).

Persistent infection also has important implications for survivors themselves. Increasing evidence indicates that Ebola virus disease can result in a constellation of long-term health effects commonly referred to as Post-Ebola Syndrome or Long Ebola, including chronic fatigue, musculoskeletal pain, headache, visual impairment, hearing loss, neurocognitive dysfunction, depression, anxiety, sleep disturbance, and other persistent neurological and systemic symptoms that may continue months to years after acute infection (Vetter et al., 2016; Scott et al., 2016; Mattia et al., 2016; Tiffany et al., 2016). Although the underlying biological mechanisms differ from those proposed for Long COVID, both conditions illustrate a broader principle: the health burden of an outbreak extends beyond acute survival. Long-term disability, persistent symptoms, recurrent healthcare utilization, reduced workforce participation, and ongoing survivor monitoring may continue long after transmission has declined. From a preparedness perspective, these downstream consequences should be incorporated into outbreak planning alongside acute morbidity and mortality, particularly when persistent infection, immune dysregulation, or viral recrudescence have been documented.

This paper proposes Sequential Pathogen Burden™ as a systems framework for understanding how successive infections, latent reactivation, microbial interaction, and cumulative immune remodeling influence long-term health following major infectious events. Rather than replacing acute-infection models, it extends the biological timeline beyond recovery and recognizes that pathogens rarely act in isolation across a lifetime. Building on this foundation, the paper introduces three quantitative preparedness models: the Immune Fragility Population™ (IFP-US™) for estimating hidden host vulnerability, the Ebola Host Susceptibility Mortality Shift™ (EHS-MS™) for projecting excess mortality during high-consequence outbreaks, and the Immune Fragility Economic Burden™ (IFEB™) framework for estimating the long-term societal costs of a changing post-pandemic immune landscape.

2. Beyond Recovery: Viral Persistence Across Human Disease

The assumption that infection ends when symptoms resolve has shaped practice for generations. Clinical recovery has marked the conclusion of surveillance and treatment for many viral illnesses. Advances in molecular diagnostics, tissue pathology, and longitudinal cohorts have increasingly shown that recovery is only one stage within a longer biological timeline. Across viral families, pathogens have evolved mechanisms to evade clearance, persist within tissue compartments, establish latency, or continue interacting with the host long after acute illness resolves.

Viral persistence is not a single phenomenon. DNA viruses such as Epstein-Barr virus, cytomegalovirus, herpes simplex virus, and varicella-zoster virus establish lifelong latency in specific tissues, reactivating when immune surveillance changes. Ebola virus demonstrates persistent low-level infection within immune-privileged sites rather than classical latency. HIV maintains stable reservoirs despite therapy, and hepatitis B persists as viral DNA in hepatocytes after apparent recovery. SARS-CoV-2 occupies an intermediate and still-debated position, with growing evidence for persistent antigen, viral RNA, and tissue-specific reservoirs in subsets of patients (Peluso et al., 2024; Stein et al., 2022; Henrich et al., 2025; Gaebler et al., 2021). Persistence therefore exists along a continuum rather than as a binary of cleared versus not cleared: residual RNA without replication, persistent antigen sustaining immune activation, replication-competent virus in reservoirs, classical latency, episodic reactivation, or, rarely, recrudescence causing renewed disease.

The latency family: EBV, HSV, VZV, CMV

Four common human herpesviruses share a single strategy: rather than eliminating them, the immune system negotiates a lifelong truce, and the durability of that truce is a property of the host's immune state rather than a fixed guarantee. When immune control slips, the virus reactivates. This is the mechanistic core of Sequential Pathogen Burden, because a disruptive infection such as COVID-19 can be the event that loosens control over viruses acquired decades earlier.

Epstein-Barr virus persists for life in B cells and reactivates when surveillance falters. Studies of Long COVID have repeatedly found serological evidence of EBV reactivation at elevated rates, though much of that signal is serological rather than demonstrated ongoing viremia, which matters for transmissibility but less for host disease. EBV is also a central suspect in autoimmunity, linking reactivation to durable host burden (Naderi et al., 2025).

Herpes simplex virus is the textbook case of neural latency, retreating into sensory neurons and reactivating under stress, illness, or immune suppression. It illustrates the rule that binds this family: the pathogen is controlled, not cleared.

Varicella-zoster virus persists in neural ganglia after primary chickenpox and reactivates decades later as shingles. Reactivation is not only an individual burden. A retrospective cohort of over 2.4 million patients found that COVID-19 was associated with a significantly elevated one-year risk of herpes zoster (hazard ratio 1.59), with the more transmissible disseminated form elevated further (hazard ratio 2.80), and active zoster lesions can transmit VZV to a susceptible contact and cause primary chickenpox (Chen Y.C. et al., 2023). This is the clearest illustration of a core SPB mechanism: reactivation driven by one infection can seed new transmission of a second, on a route and timeline the original isolation never accounted for.

Cytomegalovirus persists in most adults and exerts a quieter structural effect, reshaping the immune system over time and driving T-cell populations associated with immune aging. Its acute spread is limited by high seroprevalence, but its stakes concentrate sharply in pregnancy, where congenital CMV is a leading infectious cause of birth defects, and in the immunocompromised. CMV is the reminder that persistence can be costly even when silent, by remodeling the terrain rather than causing overt disease.

Ebola virus: the immune-privileged reservoir

Ebola illustrates the principle with unusual clarity, with the important caveat that most primary evidence involves Zaire ebolavirus rather than the Bundibugyo virus driving the current outbreak. Survivors frequently recover clinically, yet the virus can persist in the eye, testes, central nervous system, and brain ventricular system. In a nonhuman primate study of monoclonal-antibody-treated survivors, approximately 20 percent retained persistent Ebola virus infection within the brain ventricular system despite clearance from other organs, and some later developed fatal recrudescent disease (Liu et al., 2022). Broader literature has documented viral RNA and, in some contexts, viable virus in semen, ocular fluid, and central nervous system compartments months to years after acute infection, creating both survivor-health and rare high-consequence transmission concerns (Vetter et al., 2016; Meek et al., 2025). The 2021 resurgence in Guinea was genetically linked to persistence from the 2013 to 2016 West African epidemic rather than a new spillover, indicating latency on the order of years (Keita et al., 2021). This 20 percent persistence finding and the immune-privileged reservoir concept are stated here once and referenced, rather than repeated, in later sections.

SARS-CoV-2 and latent virus reactivation

Tissue studies have identified persistent SARS-CoV-2 RNA and antigen in the gastrointestinal tract, lymphoid tissue, nervous system, and other organs months after infection. Persistence of viral material does not by itself prove ongoing replication or infectiousness, but it has shifted attention toward how prolonged host-pathogen interaction influences chronic inflammation, immune activation, and post-infectious illness. In parallel, multiple investigations have documented reactivation of latent viruses following COVID-19, including Epstein-Barr virus, cytomegalovirus, herpes simplex virus, varicella-zoster virus, HHV-6, HHV-7, and hepatitis B virus, suggesting SARS-CoV-2 may alter host-pathogen equilibrium in susceptible individuals (Naderi et al., 2025; Chen et al., 2023; Iwasaki and Putrino, 2023). Influenza sits in the frame as the contrast pathogen: largely acute, with prolonged infection rare and generally confined to the severely immunocompromised. It defines the pattern by lacking the property the others share.

Collectively, persistence, latency, immune-privileged reservoirs, and reactivation represent interconnected strategies through which viruses interact with host immunity across months, years, or decades. The mechanisms differ substantially between pathogens, and this paper does not argue they behave identically. This review complements CYNAERA's The Pathophysiology of Infection-Associated Chronic Conditions, which frames IACCs as multi-system conditions shaped by persistent immune, autonomic, vascular, and inflammatory disruption. Sequential Pathogen Burden extends that work by asking how persistent viral biology and subsequent exposures continue reshaping the host after the initial illness appears to resolve.

3. From Co-Infection to Sequential Pathogen Burden

For decades, infectious disease research has focused on identifying individual pathogens and understanding how simultaneous infections influence severity. Concepts such as co-infection, superinfection, and secondary infection advanced understanding of bacterial pneumonia following influenza and opportunistic infection in immunocompromised patients. COVID-19 accelerated this work, demonstrating that pathogen interactions influence hospitalization, intensive care use, and mortality (Narasaraju et al., 2024; Musuuza et al., 2021; Feldman and Anderson, 2021).

Yet most of this literature centers on pathogens occurring simultaneously or within a narrow clinical window. Comparatively little attention has been directed toward how repeated infectious events accumulate across months or years after a major insult. For many individuals, infection is not a single episode followed by complete recovery. It is an evolving history that may include persistent viral biology, latent reactivation, recurrent respiratory infections, secondary bacterial complications, opportunistic fungal infection, antimicrobial exposure, environmental stress, and changing immune resilience. Each event occurs within the biological landscape created by those preceding it, so infection history itself may become a determinant of future health.

Sequential Pathogen Burden addresses this gap. It describes the cumulative biological impact of successive infections, latent reactivation, microbial dysbiosis, immune remodeling, and incomplete recovery following a major infectious event. Rather than replacing co-infection or infection-associated chronic conditions, it extends these models across time.

Traditional Infectious Disease Models Compared with Sequential Pathogen Burden

Traditional framework	Sequential Pathogen Burden framework
Focuses on a single infectious episode	Examines cumulative infectious history
Primarily evaluates acute disease	Includes post-acute biological change
Co-infections occur simultaneously	Sequential infections occur across months or years
Recovery concludes the clinical timeline	Recovery begins continued biological observation
Pathogen characteristics drive modeling	Pathogen biology and host trajectory modeled together
Measures immediate clinical outcomes	Includes long-term resilience and cumulative burden

The distinction is subtle but important. A patient with uncomplicated seasonal influenza represents a different biological scenario than a patient who develops COVID-19, experiences Epstein-Barr virus reactivation months later, contracts influenza the following winter, develops secondary bacterial pneumonia, and later experiences herpes zoster. Conventional surveillance records these as separate events. SPB proposes they also be understood collectively, as one evolving biological trajectory. The significance lies not in the number of infections but in the cumulative interaction between pathogens, immune regulation, tissue recovery, and physiological reserve over time.

Two consequence tracks

The pathogens that concern Sequential Pathogen Burden share one property: acute resolution does not equal clearance. That single property forks into two distinct consequences, and keeping them separate is essential, because they carry different evidence bases and different preparedness implications. Persistence, reactivation, and hiding in immune-privileged compartments can produce delayed infectious risk, a transmission consequence. Immune remodeling and T-cell exhaustion drive host disease burden, an immunopathology consequence that does not make anyone infectious. A pathogen earns its place in the SPB frame by driving either track, or both.

Track	Consequence	Illustrative pathogens
Track A: host burden	Reshapes immunity, drives chronic disease and functional decline. Not transmissible.	EBV (heavy), CMV, SARS-CoV-2 immune remodeling
Track B: transmission	Persists or reactivates into delayed infectious risk on a new route and timeline.	Ebola (near-pure), VZV reactivation to varicella, immunocompromised SARS-CoV-2 shedding
Both tracks	Drives host burden and delayed transmission together.	VZV and SARS-CoV-2 span both

This fork does three things at once. It makes the roster non-arbitrary by defining the property that earns inclusion. It prevents a common objection, that immune remodeling has nothing to do with transmission, by separating the two consequences rather than blurring them. And it tells the framework which evidence proves which limb, so that host-burden claims and transmission claims are never asked to carry each other's weight.

Measuring Sequential Pathogen Burden

Frameworks become most valuable when they move from description to measurable systems. Concepts such as the basic reproduction number, disability-adjusted life years, and excess mortality transformed public health by quantifying complex phenomena. SPB is intended to serve a similar purpose for cumulative infectious history. It is not currently intended to produce a single diagnostic number. It functions as a systems framework integrating multiple biological domains, whose interaction is the central object of study.

Proposed Components of Sequential Pathogen Burden

Domain	Illustrative variables
Infection history	Number of infections, reinfections, pathogen diversity, timing between events
Persistent biology	Viral persistence, latent reactivation, persistent antigen (Peluso et al., 2024; Stein et al., 2022)
Secondary complications	Bacterial superinfection, fungal infection, opportunistic pathogens (Narasaraju et al., 2024)
Host response	Immune dysregulation, autonomic dysfunction, endothelial injury, chronic inflammation (Naderi et al., 2025)
Functional recovery	Duration of recovery, recurrent symptoms, hospitalization, disability
Environmental modifiers	Air quality, mold exposure, heat, occupational and socioeconomic factors
Long-term outcomes	Chronic conditions, healthcare utilization, workforce participation (Davis et al., 2023)

These domains are not independent. An otherwise healthy individual with two uncomplicated respiratory infections may show minimal long-term burden, whereas another with repeated SARS-CoV-2 infections, latent reactivation, environmental stressors, bacterial complications, and delayed recovery may follow a very different trajectory despite a similar infection count. Pathogen count alone is unlikely to capture the complexity of post-acute disease. This framework builds directly on the Primary Chronic Trigger framework, which identifies the initiating event that begins chronic disease, and US-CCUC, which shows that conventional surveillance underestimates the infection-associated chronic illness population. SPB proposes that the trigger is only the beginning of a longer timeline shaped by subsequent events.

4. The Immune Fragility Population (IFP-US)

A foundational assumption of preparedness is that, outside recognized high-risk groups, the general population can be treated as biologically homogeneous. Models stratify by age, pregnancy, vaccination, or known immunocompromise while assuming the remainder is a stable healthy baseline. COVID-19 challenges that assumption, because SARS-CoV-2 has become a repeated population-level exposure rather than a single historical event. Reinfections are now common. In the Managua household cohort, 97.6 percent of participants had evidence of infection by October 2024 (99.7 percent of adults), and among those infected, roughly half had experienced two or more infections over the study period (44.0 percent one infection, 33.0 percent two, 13.6 percent three or more), demonstrating how repeated exposure becomes embedded in ordinary population biology (Maier et al., 2025). Notably, that cohort found acute reinfections became progressively milder; this does not contradict Sequential Pathogen Burden but sharpens its scope, since SPB concerns cumulative post-acute burden rather than acute severity, and asks what accumulates beneath an increasingly mild acute presentation.

Large observational studies show reinfection increases the risk of Long COVID and multisystem complications, and surveillance suggests post-infectious chronic illness is accumulating rather than resolving. In a 58-hospital analysis, validated computable phenotyping identified post-acute sequelae in 16.28 percent of COVID-19 patients, roughly twice the burden detected through diagnostic-code surveillance, with 89.31 percent of identified cases involving chronic conditions and prevalence rising through mid-2024 (JAMA Network Open, 2026).

Using US-CCUC, CYNAERA's updated 2026 model estimates that approximately 75 to 90 million Americans currently live with at least one infection-associated chronic condition (IACC), with 25 to 35 million experiencing multiple overlapping IACCs. These individuals represent the highest-risk segment of the post-pandemic host landscape. This US-CCUC estimate is stated here once and referenced in later sections rather than repeated.

The corrected IACC population is unlikely to represent the full biological impact of the pandemic. Millions report increased respiratory infection frequency, prolonged recovery after influenza or RSV, recurrent infections, shingles, or reduced exercise tolerance despite never receiving a Long COVID, ME/CFS, or dysautonomia diagnosis. They remain employed and active, yet describe measurable decline in physiological resilience. Because they rarely meet formal diagnostic criteria, they remain largely invisible to surveillance, consistent with evidence that diagnostic coding captures well under half of post-acute cases.

To address this gap, SPB introduces the Immune Fragility Population (IFP-US): a preparedness population of individuals who do not meet criteria for a recognized IACC but may demonstrate reduced biological resilience following widespread infectious exposure. Characteristics may include increased infection frequency, slower recovery, recurrent reactivation, greater susceptibility to secondary bacterial or fungal infection, prolonged post-infectious symptoms, or diminished physiological reserve. IFP-US is not a diagnostic category or disease prevalence estimate. It is a preparedness modeling construct for hidden host vulnerability that conventional surveillance does not capture.

A note on method: scenario parameters and missingness grading

The three constructs that follow (IFP-US, EHS-MS, and IFEB) are built on scenario parameters, that is, expert-elicited multipliers, rather than causal point estimates. This is a deliberate choice for a documented reason: primary studies quantifying post-pandemic immune fragility at population scale do not yet exist, because the exposure is only six years old and conventional surveillance was never designed to capture post-acute host resilience. That absence is a system-level missingness condition, a documented surveillance gap, and not evidence that the effect is absent. Under these conditions, a framework should be graded not by whether a confirmatory prevalence study has been published, but by four properties, which the constructs below are explicitly built to satisfy.

Grading axis	How the SPB constructs are built to satisfy it
Structural coherence	Each multiplier is applied to an independently derived baseline, the corrected US-CCUC IACC population, so the construct's logic holds regardless of the multiplier's exact value.
Triangulation rigor	Every scenario parameter is anchored to multiple independent evidence streams, including reinfection cohorts, EHR phenotyping, and survivor-persistence studies, rather than a single source.
Transparency of assumptions	Every multiplier value and its full scenario range is stated explicitly, so a reader can substitute a different coefficient and recompute the result.
Falsifiability pathway	Each construct makes a measurable prediction that stratified surveillance could confirm or refute, rather than an untestable assertion.

The multiplier ranges throughout are chosen conservatively relative to the size of the documented gap, and each is labeled where it is used. These are preparedness scenarios for planning under uncertainty, not disease prevalence claims.

To make the construct operational, CYNAERA introduces the Immune Fragility Multiplier (IFM), which applies a scenario multiplier to the corrected IACC baseline. The multiplier is an expert-elicited scenario parameter, not a single causal estimate, anchored in four evidence domains: reinfection frequency, reinfection-associated post-acute risk, surveillance under

-detection, and chronic post-acute disease burden. Reinfection-associated risk is supported by RECOVER pediatric data showing a 2.08-fold increased risk of documented post-acute sequelae after reinfection, with elevated risk across multiple organ systems (Zhang et al., 2026).

Surveillance under-detection and chronicity are supported by the 58-hospital cohort above. The multiplier values below are deliberately conservative relative to the size of the documented surveillance gap. Against the four grading axes, the IFM satisfies structural coherence by riding an independently derived US-CCUC baseline, triangulation by anchoring to four distinct evidence domains, transparency by presenting its full scenario range, and falsifiability by predicting a measurable excess of resilience-marker abnormality in the modeled population that targeted testing could confirm or refute.

Immune Fragility Multiplier (IFM) - US Formula:

IFP-US  =  IACC-US  ×  IFM

Immune Fragility Multiplier: Scenario Calculation

Scenario	IACC-US anchor	IFM	IFP-US calculation	Estimated IFP-US
Conservative	80 million	0.50	80M × 0.50	40 million
Moderate	82.5 million	0.85	82.5M × 0.85	70 million
High	90 million	1.10	90M × 1.10	99 million (~100 million)

The conservative scenario assumes immune fragility beyond corrected IACC burden exists but is smaller than the IACC population. The moderate scenario assumes it approaches the lower bound of the corrected IACC range. The high scenario assumes subclinical fragility may exceed diagnosed burden because many affected individuals remain functional and uncoded.

CYNAERA Post-Pandemic Host Landscape Scenarios

Scenario	IACC population	IFP-US population	Combined higher-risk	% of US population
Conservative	75 million	40 million	115 million	34%
Moderate	82.5 million	70 million	152.5 million	45%
High	90 million	100 million	190 million	56%

Based on an estimated US population of approximately 340 million. These are preparedness scenarios, not disease prevalence estimates. They evaluate how assumptions about host resilience influence projections of healthcare demand, severe illness, and outbreak response.

These scenarios do not suggest that half of Americans are immunocompromised or chronically ill. They propose that immune resilience after the pandemic is likely distributed along a continuum rather than as a simple healthy-versus-vulnerable split. Individuals with IACCs represent the highest-risk group; the Immune Fragility Population recognizes a potentially larger group whose biological reserve may have shifted enough to influence susceptibility, recovery, and cost during future outbreaks without meeting current diagnostic definitions. As US-CCUC extended understanding of hidden chronic disease prevalence, IFP-US extends that logic into preparedness by estimating hidden preparedness vulnerability rather than hidden disease.

5. Ebola Host Susceptibility Mortality Shift (EHS-MS)

The 2026 Bundibugyo virus outbreak provides a real-world application of Sequential Pathogen Burden, because it shows how preparedness models may underestimate mortality when they assume the host population is biologically equivalent to the pre-2020 population. Outbreak forecasting has focused on pathogen characteristics: transmissibility, virulence, reproductive number, and healthcare capacity. Far less attention has gone to whether the biological resilience of the host population has shifted following the largest pandemic in more than a century.

As of early July 2026, the Democratic Republic of the Congo was experiencing its largest Ebola outbreak in several years. Reporting indicated 1,460 confirmed cases and 452 confirmed deaths, a crude, provisional confirmed-case fatality ratio of approximately 30.9 percent, with hundreds of cases still in isolation at the time of reporting and more than 70 confirmed infected healthcare workers as of mid-June. Because the outbreak remained active, this crude ratio should be read as a provisional snapshot rather than a final case fatality ratio, and deaths among suspected cases were substantially higher (WHO, 2026; ECDC, 2026).

Traditional models assume observed mortality reflects the interaction of virus biology and healthcare capacity. SPB proposes this is incomplete: mortality is also influenced by the biological condition of the host population. If the proportion of individuals with infection-associated chronic conditions, reduced physiological reserve, immune dysregulation, or post-viral fragility has increased since 2020, future outbreaks may generate higher mortality than historical models predict even if the virus itself has not become more virulent. This concept is supported by the persistence evidence reviewed in Section 2, including the approximately 20 percent brain-ventricular persistence in antibody-treated primate survivors (Liu et al., 2022) and the years-long survivor-linked resurgence in Guinea (Keita et al., 2021), alongside the expanding SARS-CoV-2 persistence and reactivation literature (Peluso et al., 2024; Naderi et al., 2025).

To examine the potential impact, CYNAERA introduces the Ebola Host Susceptibility Mortality Shift (EHS-MS) model. Rather than assuming mortality remains fixed at historically observed ratios, it evaluates how modest increases in host susceptibility may influence mortality while holding viral characteristics constant. The host-susceptibility shift is an explicitly hypothetical scenario parameter, presented to illustrate the method rather than to predict the trajectory of the current outbreak, and it is not tied to any single population estimate. Under the grading framework introduced in Section 4, its falsifiability pathway is direct: the model predicts that outbreaks encountering populations with higher documented immune-fragility burden should show elevated case fatality relative to historical baselines, a prediction that stratified outbreak surveillance could test.

Ebola Host Susceptibility Mortality Shift (EHS-MS) Formula:

Projected deaths  =  Confirmed cases  ×  Baseline CFR  ×  Host susceptibility shift

Scenario	Host shift	Projected deaths	Excess deaths
Baseline	1.00×	452	0
Low shift	1.05×	475	+23
Moderate shift	1.10×	497	+45
High shift	1.20×	542	+90
Severe shift	1.30×	588	+136

Ebola Host Susceptibility Mortality Shift: Scenarios (1,460 cases) Small shifts in host susceptibility can produce meaningful differences in mortality during high-consequence outbreaks. A 5 percent increase above baseline generates roughly 23 additional deaths at the current outbreak size, and a 20 percent increase roughly 90, without any change in viral genetics, transmissibility, or baseline virulence. As outbreaks expand, these differences compound.

Ebola Excess Mortality Projection by Outbreak Size

Confirmed cases	Baseline (30.9%)	+5% shift	+10% shift	+20% shift	+30% shift
1,500	464	487 (+23)	510 (+46)	556 (+93)	603 (+139)
2,500	773	811 (+39)	850 (+77)	927 (+155)	1,005 (+232)
5,000	1,545	1,622 (+77)	1,700 (+155)	1,854 (+309)	2,009 (+464)
10,000	3,090	3,245 (+155)	3,399 (+309)	3,708 (+618)	4,017 (+927)

At a standardized 10,000-case scenario, a 10 percent increase in host susceptibility yields more than 300 excess deaths and a 20 percent increase more than 600, despite no change in the virus. Because outbreaks evolve over months, even modest shifts in host resilience may translate into meaningful differences in healthcare demand, survivor monitoring, and mortality.

Ten-Year Ebola Excess Mortality Stress Test (5,000 cases per year)

Host scenario	Annual deaths	Annual excess	Ten-year excess
Baseline	1,545	0	0
Low (1.05×)	1,622	+77	+770
Moderate (1.10×)	1,700	+155	+1,550
High (1.20×)	1,854	+309	+3,090
Severe (1.30×)	2,009	+464	+4,640

If future outbreaks repeatedly encounter populations with progressively greater immune fragility, modest per-outbreak increases accumulate into thousands of additional deaths over time. These projections are not predictions of the current outbreak. They demonstrate how small changes in host resilience generate substantial cumulative mortality across successive high-consequence outbreaks. Host susceptibility is unlikely to be a single mechanism; it reflects the cumulative interaction of chronic conditions, immune dysregulation, latent reactivation, repeated infection, chronic inflammation, nutritional stress, healthcare disruption, and coexisting infection. SPB therefore proposes a shift from pathogen-centered toward host-pathogen preparedness. The question is not only whether the virus has changed, but whether the population it encounters has changed.

A species caveat belongs here, stated as a bounded strength rather than a hidden weakness. The deepest mechanistic persistence evidence, including the 20 percent brain-ventricular finding, derives from Zaire ebolavirus, and approved filovirus therapeutics and vaccines target Zaire specifically. The current outbreak is Bundibugyo virus, a genetically distinct species. Post-filovirus survivorship and immune-privileged persistence are nonetheless increasingly understood as properties of the genus rather than of one species: a 2025 cross-sectional study of 40 Bundibugyo survivors documented persistent multisystem sequelae and physiological remodeling sixteen years after infection, an earlier two-year antibody study of the same cohort described post-Ebola syndrome with viral persistence and autoimmunity as candidate mechanisms, and a 2025 Sudan virus primate study found immune-privileged persistence posited to extend to humans given shared pathogenesis (Meek et al., 2025; Vetter et al., 2016).

The reasonable position, and the one adopted here, is that long-term sequelae in Bundibugyo survivors are directly documented, while replication-competent persistence in Bundibugyo specifically is likely but not yet mechanistically confirmed. Accordingly, the host-susceptibility parameter is kept generic and illustrative rather than tied to Zaire-derived or United States-derived coefficients when applied to the current outbreak.

6. The Immune Fragility Economic Burden (IFEB)

Economic consequences of infectious disease have traditionally been estimated by measuring direct costs of acute infection, hospitalization, pharmaceuticals, mortality, and long-term disability, evaluating each pathogen largely as an independent event. SPB proposes this no longer reflects the biological reality of the post-pandemic era. Rather than estimating the burden of a single disease, it models the cumulative economic consequences of a population whose biological resilience has shifted following repeated exposures. The question changes from what Long COVID costs to what a biologically less resilient population costs over time.

This burden extends beyond diagnosed IACCs to include the Immune Fragility Population, recurrent infection, prolonged recovery, reactivation, secondary bacterial and fungal infection, increased healthcare utilization, workforce disruption, educational interruption, and caregiver burden. Under the moderate scenario, approximately 152.5 million Americans fall within the combined higher-risk population. This is a preparedness planning figure, not a disease prevalence calculation.

CYNAERA Immune Fragility Economic Domains

Economic domain	Examples of burden
Healthcare utilization	Primary and specialty care, emergency visits, hospitalization, rehabilitation, diagnostics, pharmaceuticals
Workforce productivity	Absenteeism, presenteeism, reduced productivity, disability, early retirement
Education	Student absenteeism, caregiver work loss, special education support, reduced attainment
Public health and preparedness	Surveillance, outbreak response, vaccination, laboratory capacity, emergency planning
Long-term societal costs	Informal caregiving, insurance expenditure, disability programs, reduced economic output

The Immune Fragility Economic Burden (IFEB) Formula:

IFEB  =  Healthcare + Productivity + Preparedness + Caregiving + Secondary infection

Biological vulnerability generates cost long before hospitalization: outpatient visits, repeated prescriptions, delayed recovery, recurrent infection, intermittent work absence, caregiving, and expanded surveillance all contribute. Because long-term national data on post-pandemic immune fragility are not yet available, IFEB uses scenario modeling over a ten-year planning horizon. These scenarios assume modest annual increases in utilization, productivity loss, recurrent infection, caregiver burden, and preparedness expenditure, and do not require catastrophic assumptions. Consistent with the grading framework in Section 4, the absence of national fragility data is a system-level missingness condition rather than a reason to omit the estimate; the model states its per-capita assumptions transparently and is falsifiable through its prediction of measurable excess healthcare utilization and productivity loss in the combined higher-risk cohort relative to the resilient population.

Ten-Year United States Immune Fragility Economic Burden

Scenario	Combined higher-risk population	Estimated ten-year burden
Conservative	115 million	$900 billion
Moderate	152.5 million	$1.8 trillion
High	190 million	$3.4 trillion

The implications expand globally. Long COVID alone has been estimated to cost roughly $1 trillion annually, approximately one percent of global GDP, suggesting post-pandemic immune fragility represents a broader economic risk extending beyond any single diagnosis (Al-Aly et al., 2024).

Ten-Year Global Immune Fragility Economic Burden

Scenario	Estimated global burden
Conservative	$5 trillion
Moderate	$11 trillion
High	$20 trillion

These estimates reflect increased healthcare utilization, reduced workforce productivity, educational disruption, repeated outbreaks, expanded public health infrastructure, caregiver burden, and secondary complications across high-income and low-resource settings. They do not include indirect macroeconomic effects from instability, workforce shortages, supply-chain disruption, or climate-sensitive disease emergence, and therefore likely represent conservative planning scenarios. Every subsequent influenza season, RSV surge, bacterial outbreak, fungal epidemic, or emerging zoonotic pathogen enters a host population that may carry greater cumulative vulnerability than the one on which historical models were built. IFEB offers policymakers a scalable tool for estimating that cumulative impact (Cutler, 2022; Al-Aly et al., 2024; US-CCUC, 2026).

7. Toward Host-Centered Preparedness

The COVID-19 pandemic expanded scientific understanding of persistence, immune dysregulation, latent reactivation, and infection-associated chronic illness, yet many resulting questions remain unexplored within preparedness science. Existing outbreak models emphasize transmission, case fatality, healthcare capacity, and countermeasures, while comparatively little attention has been directed toward how cumulative infectious history may influence future outbreaks. Several questions warrant immediate investigation:

• Does repeated SARS-CoV-2 infection alter long-term immune resilience in ways that influence susceptibility to unrelated pathogens?

  
  

• How frequently do latent reactivations contribute to prolonged recovery following common infections?

  
  

• Are there recognizable sequences of viral, bacterial, and fungal infection that predict chronic disease or functional decline, and does pathogen order matter independently of pathogen identity?

  
  

• Can longitudinal monitoring of infectious history improve prediction of hospitalization, disability, or healthcare utilization?

  
  

• Should survivor monitoring become routine for selected pathogens, as it already is for Ebola?

No evidence currently demonstrates that prior SARS-CoV-2 infection increases susceptibility to Bundibugyo virus disease. But preparedness science should not wait for definitive evidence before considering plausible high-consequence scenarios. Long COVID, multisystem inflammatory syndrome, and post-Ebola syndrome all became recognized only after clinicians identified patterns existing frameworks failed to explain. Preparedness requires investigating biologically plausible questions before they become crises.

Future surveillance may benefit from expanding beyond acute measures. In addition to infections, hospitalizations, and deaths, preparedness frameworks could evaluate post-acute recovery trajectories, persistent immune abnormalities, latent viral activity, sequential infectious events, and long-term functional outcomes. This perspective has implications beyond public health agencies: schools, universities, military installations, correctional facilities, long-term care, and health systems all manage populations experiencing repeated exposures over time, and may benefit from examining cumulative infectious history rather than treating each outbreak as independent. This systems approach connects to CYNAERA's VitalGuard environmental flare-risk framework, which models how environmental conditions influence biological stability, and to the broader IACC implementation work on integrating these conditions into health systems.

8.  Conclusion: The Next Generation of Preparedness

Modern infectious disease preparedness has achieved extraordinary success by understanding pathogens. Surveillance systems detect outbreaks, laboratories characterize viral evolution, and public health interventions interrupt transmission and reduce mortality. These achievements remain the foundation of outbreak response and will continue to guide preparedness for decades to come.

COVID-19 revealed an additional dimension of infectious disease biology that preparedness has only begun to measure. Viral persistence, latent pathogen reactivation, immune remodeling, infection-associated chronic conditions, and prolonged functional impairment demonstrate that the biological consequences of infection often extend well beyond the acute illness itself. Research across SARS-CoV-2, Ebola virus, Epstein-Barr virus, cytomegalovirus, herpes simplex virus, varicella-zoster virus, and other persistent pathogens increasingly suggests that recovery is not always synonymous with complete biological resolution (Peluso et al., 2024; Proal and VanElzakker, 2021; Stein et al., 2022; Naderi et al., 2025; Liu et al., 2022; Keita et al., 2021; Virgin, Wherry and Ahmed, 2009).

Sequential Pathogen Burden organizes these observations into a unified preparedness framework. Rather than viewing infections as isolated clinical events, SPB recognizes that successive infections occur within hosts whose biology has already been shaped by previous infectious exposures. The framework does not propose that every infection produces lasting biological change or that all persistent pathogens behave identically. Instead, it argues that cumulative infectious history represents an underrecognized determinant of future resilience, recovery, and preparedness (Adinig, PCT, 2026; Adinig, US-CCUC, 2026).

The three constructs introduced in this paper extend that concept into measurable preparedness models. The Immune Fragility Population estimates hidden biological vulnerability beyond recognized chronic disease. The Ebola Host Susceptibility Mortality Shift demonstrates how relatively small changes in host resilience may substantially increase mortality during future outbreaks despite no change in pathogen virulence. The Immune Fragility Economic Burden projects that the cumulative effects of reduced population resilience could generate approximately $900 billion to $3.4 trillion in U.S. costs and $5 trillion to $20 trillion globally over the coming decade under modeled planning scenarios. Together, these frameworks suggest that preparedness planning should account not only for pathogens themselves, but also for the changing biological characteristics of the populations they encounter (WHO, 2026; ECDC, 2026; Cutler, 2022; Al-Aly et al., 2024; Adinig, US-CCUC, 2026).

Perhaps the most significant implication extends beyond COVID-19 or Ebola. Using current US-CCUC estimates together with the proposed Immune Fragility Population, approximately 115 to 190 million Americans, representing 34% to 56% of the U.S. population, may fall outside the traditional assumption of a uniformly resilient host population. These figures are not presented as disease prevalence estimates but as preparedness scenarios illustrating how hidden biological vulnerability could influence healthcare demand, outbreak severity, workforce participation, and long-term economic resilience (Adinig, US-CCUC, 2026).

History offers a cautionary precedent. Measles-induced immune amnesia remained largely invisible for decades despite increasing mortality from unrelated infections because surveillance systems were never designed to detect the underlying biological change. The lesson is not that SARS-CoV-2 acts through the same mechanism. Rather, it is that important population-level changes in immune biology can remain hidden long after acute outbreaks have ended when the wrong questions are being measured (Mina et al., 2019).

Future influenza pandemics, filovirus outbreaks, antimicrobial-resistant pathogens, climate-sensitive infectious diseases, and emerging zoonotic threats will not encounter the same global population that existed before 2020. They will encounter populations shaped by repeated SARS-CoV-2 infections, evolving immune histories, infection-associated chronic conditions, persistent viral biology, and cumulative pathogen exposure (Altmann et al., 2023; Brodin and Casari, 2023; Zhang et al., 2026; Maier et al., 2025).

Preparedness has become exceptionally good at measuring pathogens. The next generation of preparedness may also need to measure what those pathogens leave behind. If the population has changed, preparedness must evolve with it.

How to Cite This Article

Adinig, C. (2026). COVID-19 and Ebola: Rethinking Pandemic Preparedness After the World's Largest Pandemic. CYNAERA Institute. Retrieved from https://www.cynaera.com/post/ebola-pathogen-burden

Frequently Asked Questions

What is Sequential Pathogen Burden, and why does it matter after COVID-19?

Sequential Pathogen Burden (SPB) is a CYNAERA preparedness framework describing how repeated infections, viral reactivation, bacterial or fungal complications, immune remodeling, and incomplete recovery may accumulate over time following a major infectious event such as COVID-19. Rather than viewing infections as isolated events, SPB examines how cumulative infectious history may influence future health, resilience, and outbreak preparedness.

How is Sequential Pathogen Burden different from co-infection?

Co-infection refers to two or more pathogens occurring at the same time. Sequential Pathogen Burden examines what happens when infections occur over months or years, such as COVID-19 followed by Epstein-Barr virus reactivation, influenza, bacterial pneumonia, shingles, or fungal complications. The focus is cumulative biological burden rather than simultaneous infection.

Why does Ebola matter in a paper about COVID-19?

The current Ebola outbreak illustrates an important preparedness question rather than a direct connection between the two viruses. Ebola demonstrates that some infections can persist after apparent recovery, contribute to long-term survivor complications, and in rare cases recrudesce. This paper asks whether future Ebola and other outbreaks should account for a post-COVID host population that may differ biologically from the one that existed before 2020.

Can COVID-19 reactivate latent viruses such as Epstein-Barr virus (EBV) or shingles?

Yes. Multiple studies have reported reactivation of latent viruses following COVID-19, including Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (shingles), HHV-6, HHV-7, and hepatitis B virus (Naderi et al., 2025). Proposed mechanisms include immune dysregulation, persistent inflammation, and altered immune surveillance.

Does viral reactivation after COVID-19 mean someone becomes contagious again?

Not necessarily. Viral reactivation means a previously controlled virus has become biologically active. Whether someone becomes contagious depends on the specific virus, the tissues involved, viral shedding, immune status, and whether infectious virus is present. SPB treats this as a pathogen-specific research and preparedness question rather than a universal assumption.

Does this paper claim COVID-19 caused the current Ebola outbreak?

No. The paper does not argue that COVID-19 caused Ebola or increased Ebola transmission. Instead, it asks whether future preparedness models should consider a host population that has experienced widespread SARS-CoV-2 infection, repeated reinfections, infection-associated chronic conditions, and potential changes in biological resilience.

What is the Immune Fragility Population (IFP-US)?

The Immune Fragility Population is a preparedness construct introduced in this paper to describe individuals who may have reduced biological resilience following widespread infectious exposure despite not meeting diagnostic criteria for recognized infection-associated chronic conditions. It is intended for preparedness planning and scenario analysis, not as a medical diagnosis.

Is Sequential Pathogen Burden a medical diagnosis or disease?

No. Sequential Pathogen Burden is a research and preparedness framework. It is designed to help researchers and policymakers understand how cumulative infectious history may influence recovery, future outbreaks, healthcare demand, mortality, and long-term economic burden.

What are the main findings of this paper?

Using CYNAERA's preparedness scenarios, the paper estimates:

• 75 to 90 million Americans living with at least one infection-associated chronic condition.

• 40 to 100 million additional Americans who may belong to the proposed Immune Fragility Population.

• A combined 115 to 190 million higher-risk Americans for preparedness planning.

• Up to 927 additional Ebola deaths in a standardized 10,000-case outbreak under higher host susceptibility scenarios.

• Approximately 2.8 to 4.6 billion people globally could fall within a higher-risk immune fragility population

• A projected 10-year U.S. economic burden of $900 billion to $3.4 trillion, with a potential global burden of $5 to $20 trillion.

These are preparedness scenarios intended to support planning under uncertainty rather than disease prevalence estimates.

How does Sequential Pathogen Burden connect to CYNAERA's other research?

Sequential Pathogen Burden extends CYNAERA's broader terrain intelligence architecture. It builds on the Primary Chronic Trigger (PCT™) framework by examining what happens after the initiating infection, complements US-CCUC™ by expanding hidden disease burden into hidden preparedness vulnerability, and supports frameworks such as VitalGuard™, fungal-emergence forecasting, and emergency preparedness planning by incorporating cumulative host biology into outbreak risk.

CYNAERA Framework Papers and Core Research Libraries

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• Gaming As A Digital Biomarker

• Primary Chronic Trigger (PCT)™ 

• CYNAERA Remission Standard™

• The Body First Trial Protocol™

• Long COVID Prevalence in Congress

• Long COVID Prevalence in U.S. Military

• Corrected National Prevalence Estimates for (IACCs)

• Therapeutic Polarity in Long COVID and ME/CFS

• Preliminary Findings from The Eve Research Project

• Biological Adaptive Reduction State™ (BARS™)

• The Hidden Public Health Cost of AI Data Centers

• ​Composite Diagnostic Fingerprint for Long COVID

• SymCas™: Symptom Flare Prediction in IACCs

• VitalGuard™ Environmental Flare Risk Engine

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Adinig, C. (2026). The Primary Chronic Trigger Framework: A Mathematical Blueprint for Detecting Ignition Events and Modeling Burden in Infection-Associated Chronic Conditions. SSRN. https://doi.org/10.2139/ssrn.6892100

2. Adinig, C. (2026). Corrected National Prevalence Estimates for Infection-Associated Chronic Conditions (US-CCUC). SSRN. https://doi.org/10.2139/ssrn.6967838

3. Adinig, C. (2026). The Pathophysiology of Infection-Associated Chronic Conditions. CYNAERA Institute. https://www.cynaera.com/post/pathophysiology-of-iacc

4. Adinig, C. (2026). VitalGuard: A Condition-Sensitive Environmental Flare Risk Framework for Infection-Associated Chronic Conditions. SSRN. https://doi.org/10.2139/ssrn.6848063

5. Adinig, C. (2026). The Forgotten Pandemic Threat: Climate-Driven Fungal Emergence. CYNAERA Institute. https://www.cynaera.com/post/fungal-pandemic

6. Adinig, C. (2025-2026). FEMA Wildfire Response Addendum: Protocols for Infection-Associated Chronic Conditions. CYNAERA Institute. https://www.cynaera.com/post/fema-wildfire

7. Al-Aly, Z., Davis, H., McCorkell, L., Soares, L., Wulf-Hanson, S., Iwasaki, A. and Topol, E.J. (2024). Long COVID science, research and policy. Nature Medicine, 30(8), 2148-2164. https://doi.org/10.1038/s41591-024-03173-6

8. Altmann, D.M., Whettlock, E.M., Liu, S., Arachchillage, D.J. and Boyton, R.J. (2023). The immunology of long COVID. Nature Reviews Immunology, 23(10), 618-634.

9. Brodin, P. and Casari, G. (2023). Immune dysregulation in long COVID. Nature Reviews Immunology.

10. Chen, B., Julg, B., Mohandas, S., et al. (2023). Viral persistence, reactivation, and mechanisms of long COVID. eLife, 12, e86015. https://doi.org/10.7554/eLife.86015

11. Chen, Y.C., Ho, C.H., Liu, T.H., et al. (2023). Long-term risk of herpes zoster following COVID-19: a retrospective cohort study of 2,442,686 patients. Journal of Medical Virology, 95(4), e28745. (Distinct from Chen, B., et al., 2023, eLife, above.) https://doi.org/10.1002/jmv.28745

12. Cutler, D.M. (2022). The costs of long COVID. JAMA Health Forum, 3(5), e221809. Updated July 2022 estimate approximately $3.7 trillion, United States. https://doi.org/10.1001/jamahealthforum.2022.1809

13. Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology, 21(3), 133-146. https://doi.org/10.1038/s41579-022-00846-2

14. European Centre for Disease Prevention and Control (2026). Ebola disease outbreak caused by Bundibugyo virus, DRC and Uganda: threat assessment (data to 30 June 2026: 1,460 confirmed cases, 452 deaths).

15. Feldman, C. and Anderson, R. (2021). The role of co-infections in COVID-19. Seminars in Respiratory and Critical Care Medicine.

16. Gaebler, C., et al. (2021). Evolution of antibody responses up to 1 year after SARS-CoV-2 infection. Nature.

17. Maier, H.E., Ojeda, S., Shotwell, A., et al.; Gordon, A. (2025). 1st, 2nd, and 3rd+ SARS-CoV-2 infections: associations of prior infections with protection and severity. medRxiv, 2025.04.07.25324191. Managua Household Influenza Cohort Study. https://doi.org/10.1101/2025.04.07.25324191

18. Iwasaki, A. and Putrino, D. (2023). Viral persistence and immune dysregulation in Long COVID. Nature Medicine.

19. JAMA Network Open (2026). Long COVID persistence and surveillance gaps across 58 US hospitals. JAMA Network Open, 9(5), e2614909. https://doi.org/10.1001/jamanetworkopen.2026.14909

20. Keita, A.K., et al. (2021). Resurgence of Ebola virus in 2021 in Guinea suggests a new paradigm for outbreaks. Nature, 597, 539-543. https://doi.org/10.1038/s41586-021-03901-9

21. Liu, J., Trefry, J.C., et al. (2022). Ebola virus persistence and disease recrudescence in the brains of antibody-treated nonhuman primate survivors. Science Translational Medicine, 14(631), eabi5229. https://doi.org/10.1126/scitranslmed.abi5229

22. Meek, O., et al. (2025). Ebola virus persistence: implications for human-to-human transmission and new outbreaks. Exploration of Medicine, 6, 1001333. https://doi.org/10.37349/emed.2025.1001333

23. Mina, M.J., Kula, T., Leng, Y., et al. (2019). Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens. Science, 366(6465), 599-606. https://doi.org/10.1126/science.aay6485

24. Musuuza, J.S., et al. (2021). Prevalence and outcomes of co-infection in COVID-19 patients. BMC Infectious Diseases.

25. Naderi, M., et al. (2025). The reactivation of the various types of viruses following COVID-19 infection: a systematic review. Future Virology, 20(3-4), 99-111. (Systematic review of 13 studies documenting reactivation of HHV, EBV, CMV, HBV, HSV, VZV, HHV-6, HHV-7, and HHV-8.) https://doi.org/10.1080/17460794.2025.2483122

26. Narasaraju, T.A., Chow, V.T.K. and Pandareesh, M.D. (2024). SARS-CoV-2 and influenza co-infection: fair competition or sinister combination? Viruses, 16(5), 793. https://doi.org/10.3390/v16050793

27. Peluso, M.J., et al. (2024). Tissue-based T cell activation and viral RNA persist for up to 2 years after SARS-CoV-2 infection. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.adk3295

28. Proal, A.D. and VanElzakker, M.B. (2021). Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors. Frontiers in Microbiology, 12, 698169. https://doi.org/10.3389/fmicb.2021.698169

29. Stein, S.R., et al. (2022). SARS-CoV-2 infection and persistence in the human body and brain at autopsy. Nature, 612, 758-763. https://doi.org/10.1038/s41586-022-05542-y

30. Vetter, P., Kaiser, L., et al. (2016). Ebola virus shedding and transmission: review of current evidence. The Journal of Infectious Diseases, 214(suppl_3), S177-S184. https://doi.org/10.1093/infdis/jiw254

31. Virgin, H.W., Wherry, E.J. and Ahmed, R. (2009). Redefining chronic viral infection. Cell, 138(1), 30-50. https://doi.org/10.1016/j.cell.2009.06.036

32. WHO (2026). Ebola disease caused by Bundibugyo virus, Democratic Republic of the Congo and Uganda: disease outbreak news and situation reports.

33. Zhang, B., Wu, Q., Jhaveri, R., et al.; RECOVER Consortium (2026). Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the Omicron era (RECOVER-EHR). Lancet Infectious Diseases, 26(2), 127-138. https://doi.org/10.1016/S1473-3099(25)00476-1